Go Pro
→ Your book attached (From Profits Run) (Ad)tc pixel Free CMMB Stock Alerts

Chemomab Therapeutics (CMMB) Financials

Chemomab Therapeutics logo
$1.56 +0.04 (+2.63%)
Closing price 07/17/2026 04:00 PM Eastern
Extended Trading
$1.55 -0.01 (-0.64%)
As of 07/17/2026 07:21 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for Chemomab Therapeutics

Annual Income Statements for Chemomab Therapeutics

This table shows Chemomab Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -4.74 -9.81 -13 -27 -5.95 -12 -28 -24 -14 -9.00
Consolidated Net Income / (Loss)		 -4.74 -9.81 -14 -27 -5.95 -12 -28 -24 -14 -9.00
Net Income / (Loss) Continuing Operations		 -4.74 -9.81 -13 -27 -5.95 -12 -28 -24 -14 -9.00
Total Pre-Tax Income 		-4.61 -9.48 13 -27 -5.95 -12 -28 -24 -14 -9.00
Total Operating Income		 -4.64 -9.39 -13 -23 -5.97 -12 -29 -25 -15 -9.57
Total Gross Profit		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 4.64 9.39 13 23 5.97 12 29 25 15 9.57
Selling, General & Admin Expense		 2.26 3.16 5.52 6.25 1.29 6.03 12 7.08 3.41 3.73
Research & Development Expense		 2.38 6.23 7.51 13 4.68 6.33 17 18 11 5.83
Total Other Income / (Expense), net		 0.04 -0.09 0.46 -4.23 0.02 -0.11 0.35 1.24 0.79 0.57
Other Income / (Expense), net		 0.04 0.00 0.46 -4.23 0.02 -0.11 0.35 1.24 0.79 0.57
Income Tax Expense		 0.14 0.32 0.31 - - 0.00 -0.53 0.00 0.00 0.00
Basic Earnings per Share		 $0.87 $1.09 $1.09 $0.79 $0.04 $0.06 $0.12 $0.10 $0.04 $0.02
Weighted Average Basic Shares Outstanding		 - - 12.63M 34.45K 136.76M 207.47M 227.59M 235.00M 359.05M 510.23M
Diluted Earnings per Share		 $0.87 $1.09 $1.09 $0.79 $0.04 $0.06 $0.12 $0.10 $0.04 $0.02
Weighted Average Diluted Shares Outstanding		 - - 12.63M 34.45K 136.76M 207.47M 227.59M 235.00M 359.05M 510.23M
Weighted Average Basic & Diluted Shares Outstanding		 - - 12.63M 34.45K 136.76M 207.47M 221.00M 284.09M 377.13M 575.38M

Quarterly Income Statements for Chemomab Therapeutics

No quarterly income statements for Chemomab Therapeutics are available.

Annual Cash Flow Statements for Chemomab Therapeutics

This table details how cash moves in and out of Chemomab Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 2.41 -3.31 6.18 10 -0.55 3.51 -1.65 -4.23 -3.22 1.42
Net Cash From Operating Activities		 -4.02 -8.94 -14 -16 -5.24 -12 -20 -24 -15 -11
Net Cash From Continuing Operating Activities		 -4.02 -8.94 -14 -16 -5.24 -12 -20 -24 -15 -11
Net Income / (Loss) Continuing Operations		 -4.74 -9.81 -14 -27 -5.95 -12 -28 -24 -14 -9.00
Consolidated Net Income / (Loss)		 -4.74 -9.81 -14 -27 -5.95 -12 -28 -24 -14 -9.00
Depreciation Expense		 0.04 0.05 0.07 0.28 0.02 0.03 0.06 0.07 0.05 0.07
Non-Cash Adjustments To Reconcile Net Income		 0.92 1.41 2.94 5.73 0.13 2.02 3.20 1.50 0.65 0.60
Changes in Operating Assets and Liabilities, net		 0.64 0.97 -3.43 4.66 0.56 -1.95 4.02 -0.96 -2.15 -2.80
Net Cash From Investing Activities		 -0.08 -0.03 -0.21 -0.10 -0.06 -45 20 16 2.30 5.39
Net Cash From Continuing Investing Activities		 -0.08 -0.03 -0.21 -0.10 -0.06 -45 20 16 2.30 5.39
Purchase of Property, Plant & Equipment		 - - -0.21 -0.10 -0.04 -0.24 -0.07 -0.00 0.00 -0.00
Sale of Property, Plant & Equipment		 0.08 0.03 - 0.00 0.00 1.00 - 0.00 0.00 0.00
Other Investing Activities, net		 - - - - -0.02 -46 20 16 2.30 5.39
Net Cash From Financing Activities		 6.50 5.67 21 27 4.75 61 -0.81 3.50 9.87 7.16
Net Cash From Continuing Financing Activities		 6.50 5.67 21 27 4.75 61 -0.81 3.50 9.87 7.16
Repurchase of Common Equity		 - - -2.30 - - 0.00 -1.22 0.00 0.00 0.00
Issuance of Common Equity		 - - 23 31 4.75 59 0.27 3.50 9.87 7.15
Other Financing Activities, net		 - - - -3.88 0.00 2.44 0.14 0.00 0.00 0.01
Cash Interest Received		 0.00 0.00 - - - 0.07 0.97 1.46 0.81 0.61
Cash Income Taxes Paid		 - - 0.24 - - 0.00 0.35 0.19 0.00 0.00

Quarterly Cash Flow Statements for Chemomab Therapeutics

No quarterly cash flow statements for Chemomab Therapeutics are available.

Annual Balance Sheets for Chemomab Therapeutics

This table presents Chemomab Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 2.09 13 20 12 64 43 22 17 14
Total Current Assets		 0.00 11 18 12 63 42 21 16 13
Cash & Equivalents		 - 7.52 18 12 15 14 9.29 6.07 7.56
Restricted Cash		 - - - - 0.00 0.08 0.08 0.08 0.00
Prepaid Expenses		 - - 0.64 0.14 1.53 1.77 1.04 1.70 3.06
Other Current Assets		 - - - 0.02 46 26 10 8.20 2.80
Plant, Property, & Equipment, net		 0.00 0.39 0.16 0.15 0.36 0.37 0.30 0.25 0.18
Total Noncurrent Assets		 2.09 1.46 1.39 0.49 0.40 0.96 0.95 0.67 0.21
Other Noncurrent Operating Assets		 1.69 1.24 1.39 0.49 0.40 0.96 0.95 0.67 0.21
Total Liabilities & Shareholders' Equity		 2.09 13 20 12 64 43 22 17 14
Total Liabilities		 2.70 2.96 4.85 1.67 2.89 6.84 5.15 3.43 1.48
Total Current Liabilities		 0.16 2.75 4.12 1.32 2.65 6.75 4.84 3.22 1.48
Accounts Payable		 0.16 0.40 3.73 0.09 1.34 1.69 0.52 0.63 0.49
Accrued Expenses		 - - - 0.72 0.56 3.38 3.42 1.54 0.34
Current Employee Benefit Liabilities		 - 0.64 - 0.44 0.65 1.56 0.82 0.93 0.66
Other Current Liabilities		 0.00 1.71 0.39 0.07 0.11 0.12 0.08 0.12 0.00
Total Noncurrent Liabilities		 -0.30 0.21 0.73 0.36 0.24 0.09 0.32 0.21 0.00
Other Noncurrent Operating Liabilities		 -0.45 - 0.73 0.36 0.24 0.09 0.32 0.21 0.00
Commitments & Contingencies		 - 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 2.22 9.81 15 11 61 36 17 14 12
Total Preferred & Common Equity		 2.22 9.81 15 11 61 36 17 14 12
Total Common Equity		 2.22 9.81 15 11 61 36 17 14 12
Common Stock		 - 87 119 34 98 101 106 116 124
Retained Earnings		 - -78 -105 -24 -36 -64 -89 -103 -112

Quarterly Balance Sheets for Chemomab Therapeutics

No quarterly balance sheets for Chemomab Therapeutics are available.

Annual Metrics And Ratios for Chemomab Therapeutics

This table displays calculated financial ratios and metrics derived from Chemomab Therapeutics' official financial filings.

Metric 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 0.00 0.00 15,575,682.00 15,575,682.00 37,099,352.00 11,400,756.00 220,996,240.00 284,094,700.00 377,132,220.00 575,381,320.00
DEI Adjusted Shares Outstanding		 0.00 0.00 243,370.00 243,370.00 579,677.00 2,850,189.00 55,249,060.00 71,023,675.00 94,283,055.00 575,381,320.00
DEI Earnings Per Adjusted Shares Outstanding		 0.00 0.00 -52.94 -111.45 -10.27 -4.38 -0.50 -0.34 -0.15 -0.02
Growth Metrics		 - - - - - - - - - -
Profitability Metrics		 - - - - - - - - - -
Net Operating Profit after Tax (NOPAT)		 -3.25 -6.57 -13 -16 -4.18 -8.66 -20 -18 -10 -6.70
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - -55.14% -104.85% -76.22% -54.30%
Earnings before Interest and Taxes (EBIT)		 -4.60 -9.39 -13 -27 -5.95 -12 -28 -24 -14 -9.00
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -4.56 -9.34 -13 -27 -5.93 -12 -28 -24 -14 -8.93
Valuation Ratios		 - - - - - - - - - -
Leverage & Solvency		 - - - - - - - - - -
Liquidity Ratios		 - - - - - - - - - -
Cash Flow Metrics		 - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -8.80 -13 -11 -5.97 -55 2.77 -2.82 -10 -4.08
Efficiency Ratios		 - - - - - - - - - -
Capital & Investment Metrics		 - - - - - - - - - -
Invested Capital		 0.00 2.22 2.29 -2.67 -0.87 45 23 7.63 7.39 4.77
Increase / (Decrease) in Invested Capital		 0.00 2.22 0.06 -4.95 1.79 46 -23 -15 -0.24 -2.62
Book Value per Share		 $0.00 $0.84 $0.78 $0.96 $0.29 $5.39 $3.14 $1.54 $0.05 $0.03
Tangible Book Value per Share		 $0.00 $0.84 $0.78 $0.96 $0.29 $5.39 $3.14 $1.54 $0.05 $0.03
Total Capital		 0.00 2.22 9.81 15 11 61 36 17 14 12
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 0.00 0.00 -7.52 -18 -12 -15 -14 -9.37 -6.15 -7.56
Capital Expenditures (CapEx)		 -0.08 -0.03 0.21 0.10 0.04 -0.76 0.07 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 0.00 -0.16 0.66 -3.49 -1.15 45 21 6.69 6.68 4.38
Debt-free Net Working Capital (DFNWC)		 0.00 -0.16 8.17 14 11 60 35 16 13 12
Net Working Capital (NWC)		 0.00 -0.16 8.17 14 11 60 35 16 13 12
Net Nonoperating Expense (NNE)		 1.49 3.23 1.06 11 1.77 3.82 7.67 6.40 3.63 2.30
Net Nonoperating Obligations (NNO)		 0.00 0.00 -7.52 -18 -12 -16 -14 -9.37 -6.15 -7.56
Total Depreciation and Amortization (D&A)		 0.04 0.05 0.07 0.28 0.02 0.03 0.06 0.07 0.05 0.07
Earnings Adjustments		 - - - - - - - - - -
Adjusted Basic Earnings per Share		 $0.00 $0.00 $279.04 $202.24 $79.36 $0.06 $0.12 $0.41 $0.16 $0.02
Adjusted Weighted Average Basic Shares Outstanding		 0.00 0.00 49.35K 144.92K 144.92K 228.09M 227.59M 58.75M 89.76M 510.23M
Adjusted Diluted Earnings per Share		 $0.00 $0.00 $279.04 $202.24 $79.36 $0.06 $0.12 $0.41 $0.16 $0.02
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 0.00 49.35K 144.92K 144.92K 228.09M 227.59M 58.75M 89.76M 510.23M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $279.04 $202.24 $79.36 $0.06 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 0.00 49.35K 134.56K 145.00 207.47M 221.00M 71.02M 94.28M 575.38M
Normalized Net Operating Profit after Tax (NOPAT)		 -3.25 -6.57 -13 -14 -4.18 -8.66 -20 -18 -10 -6.70
Debt Service Ratios		 - - - - - - - - - -
Payout Ratios		 - - - - - - - - - -

Quarterly Metrics And Ratios for Chemomab Therapeutics

No quarterly metrics and ratios for Chemomab Therapeutics are available.


Financials Breakdown Chart

Chemomab Therapeutics Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Chemomab Therapeutics' financial year ends in December. Their financial year 2025 ended on December 31, 2025.

Chemomab Therapeutics' net income appears to be on an upward trend, with a most recent value of -$9.00 million in 2025, rising from -$4.74 million in 2016. The previous period was -$13.95 million in 2024. View Chemomab Therapeutics' forecast to see where analysts expect Chemomab Therapeutics to go next.

Chemomab Therapeutics' total operating income in 2025 was -$9.57 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $9.57 million

Over the last 9 years, Chemomab Therapeutics' total revenue changed from $0.00 in 2016 to $0.00 in 2025, a change of 0.0%.

Chemomab Therapeutics' total liabilities were at $1.48 million at the end of 2025, a 56.9% decrease from 2024, and a 45.2% decrease since 2017.

In the past 8 years, Chemomab Therapeutics' cash and equivalents has ranged from $0.00 in 2017 to $17.58 million in 2019, and is currently $7.56 million as of their latest financial filing in 2025.

Over the last 9 years, Chemomab Therapeutics' book value per share changed from 0.00 in 2016 to 0.03 in 2025, a change of 3.3%.


Related Companies

Financial statements for NASDAQ:CMMB last updated on 7/16/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Buy this stock tomorrow
Marc Chaikin, founder of Chaikin Analytics, is flagging a little-known company that just secured a partnership...
Chaikin Analytics | Sponsoredtc pixel
The only metrics you should watch as a day trader.
Day traders and swing traders don't need the same metrics - and using the wrong ones costs you edge. After 40 ...
The TradingPub | Sponsoredtc pixel
Your withdrawal order could cost you in taxes
If you have $2M or more saved, the 4% rule points to roughly $92,000 a year - but it's a single-variable answe...
SmartAsset | Sponsoredtc pixel
Ex-CIA Insider: “Prepare for a Mid-Term Meltdown”
Former CIA and Pentagon advisor Jim Rickards - who correctly called the 2008 recession, Trump's 2016 election,...
Paradigm Press | Sponsoredtc pixel
URGENT Dollar Reset Warning for Monday
A 50-year U.S.-Saudi arrangement established under Henry Kissinger - one credited with anchoring the dollar in...
Golden Portfolio | Sponsoredtc pixel
SPCX Warning - and Worst News for Stocks in 50 Years
Goldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...
TradeSmith | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel